Background: Neuromyelitis optica (NMO) IgG is a specific marker for NMO. Furthermore, a high proportion of patients with longitudinally extensive transverse myelitis (characterized by spinal cord lesions extending 3 vertebral segments or more on magnetic resonance imaging) are seropositive for NMO-IgG and are considered to have a limited form of NMO. The NMO-IgG status in mild cases of acute partial transverse myelitis asociated with minimal magnetic resonance imaging abnormalities (spinal cord lesions Ͻ2 vertebral segments on magnetic resonance imaging) is unknown.
Results:
Of the 22 patients with acute partial transverse myelitis, only 1 was seropositive for NMO-IgG at presentation. This patient subsequently developed recurrent episodes of longitudinally extensive transverse myelitis that are typicaly seen in association with NMOIgG. Three of the 4 patients meeting criteria for NMO were seropositive. None of the patients with multiple sclerosis had NMO-IgG detected.
Conclusion: NMO-IgG is rarely encountered in patients with acute partial transverse myelitis, which is in sharp contrast to the high frequency of this antibody in patients with NMO and longitudinally extensive transverse myelitis.
Arch Neurol. 2006; 63:1398 -1400 T O OUR KNOWLEDGE, THE clinical significance of newly described neuromyelitis optica (NMO) antibodies (NMO-IgG) has been evaluated only at the Mayo Clinic, where the assay for the detection of NMO antibodies was developed recently.
1 Investigators have described a high rate of NMO antibody positivity in patients fulfilling the criteria for NMO and a low rate of positivity in patients with classic multiple sclerosis (MS). 1 In addition, 40% of patients presenting with longitudinally extensive transverse myelitis (LETM), involving at least 3 vertebral segments on magnetic resonance imaging (MRI), have been positive for NMO-IgG; these patients have a high risk of early relapse. 2 To our knowledge, the rate of NMO positivity in patients presenting with mild symptoms of acute partial transverse myelitis (APTM) involving short asymmetric lesions (Ͻ2 vertebral segments) on MRI has not been studied. We tested such a population of patients with APTM for the presence of NMO-IgG to better define the spectrum of demyelinating disease associated with NMO antibody positivity.
METHODS
Serum samples were tested at Mayo Clinic's Neuroimmunology Laboratory. All samples were tested blind to the clinical and radiologic findings. Details of the performance of this assay have been published previously. 1 We considered patients positive for NMO-IgG by immunofluorescence with titers at 1:120 or higher and those negative with titers less than 1:120. Patients chosen for the study were seen consecutively at the Allegheny Multiple Sclerosis Treatment Center, Pittsburgh, having undergone retrospec-tive medical record reviews, and all met the criteria described later. These patients have been followed up prospectively following performance of the assay for NMO antibodies.
We categorized our patients into 3 groups as follows. In group 1, APTM was defined according to the criteria published previously that included patients exhibiting mild symmetrical sensory and/or motor symptoms or marked asymmetrical motor and/or sensory symptoms. 3 All of these 22 patients had a normal cerebral MRI. All but 1 patient (with a normal spinal MRI) had small focal (n=13) or multifocal (n=8) spinal MRI lesions extending over 2 or fewer spinal cord segments. Patients with LETM at presentation were excluded. The mean follow-up at the time of NMO antibody testing was 5 years (range, 12-120 months). In patients with a lengthy follow-up, repeat cerebral MRIs were obtained every 12 to 24 months and remained negative. Group 2 patients had NMO and fulfilled previously published criteria. 4 The mean follow-up in these 4 NMO patients at the time of testing was 36 months (range, 12-105 months). In group 3, there were 6 patients with MS fulfilling the criteria of Poser et al. 5 These patients had multiple cerebral lesions on MRI and relapsingremitting features; signs and symptoms of severe myelopathy (n=2), severe recurrent optic neuritis (n=3), or both (n=1); and no other prominent symptoms indicating involvement of other components of the central nervous system. All group 3 patients had signs of spinal and optic nerve demyelination on neurological examination and spinal cord lesions demonstrated by MRI (always Ͻ2 vertebral segments). The mean follow-up was 45 months (range, 42-48 months). Patient characteristics, including disability score after stabilization or recovery, are given in the Table. Expanded Disability Status Scale (EDSS) measurements are routinely recorded in our MS clinic and were all performed by a single experienced examiner (T.F.S.). 6 Patients were considered stable for a final EDSS determination if the EDSS score was unchanged over at least 2 examinations performed at least 3 months apart.
RESULTS
In group 1, 21 (95%) of the 22 patients with APTM were seronegative for NMO antibodies. These 21 patients with APTM presented with low levels of disability and sometimes experienced mild relapses (n = 10) before NMOIgG testing. One seronegative patient developed a mild relapse during the brief follow-up since NMO-IgG testing (average clinical course, 5.5 months; range, 4-7 months).
Most group 1 patients were not taking immunosuppressants or corticosteroids at the time of NMO-IgG testing (20 [91%] of 22 patients), with a notable exception being the sole patient testing seropositive for NMO-IgG. This patient had a severe course compared with the others. She presented initially with an episode of mild APTM. The MRI obtained 10 days after the first attack of APTM showed a faint small area of increased signal at C7. Another attack occurred 14 months later, with the appearance of a longitudinally extensive lesion on MRI (from C7 to T4). This patient developed a severe relapse 5 months later, with worsening of the longitudinally extensive lesion by MRI; her EDSS score reached 8.0. 6 After treatment with high-dose corticosteroids, plasmapheresis, and methotrexate, 7.5 mg/wk, the EDSS score improved slowly over 3 months to 6.0. The patient continued to improve slowly over the next year after additional low-dose methotrexate therapy (20 mg/ wk), reaching an EDSS score of 5.5. The NMO-IgG test was performed during methotrexate treatment. The average EDSS score in the remaining patients was 2.5 (range, 0-5.0). In group 2, NMO-IgG was detected in 3 of the 4 patients with definite NMO (mean EDSS score, 6; range, 2-10). All 4 patients were being treated with long-term immunosuppressive agents at the time of testing. In group 3, none of the patients with MS tested positive for NMO-IgG (mean EDSS score, 3.5; range, 1.0-6.0).
COMMENT
This study reports that NMO-IgG is rarely present in patients with mild APTM, in sharp contrast to the high frequency in patients with recurrent LETM. 1 This study has implications regarding the way we think about TM. NMO-IgG seems to differentiate some patients with LETM from those with APTM, and has predictive and prognostic significance, suggesting that the length of the lesion in TM is important. 7 Unfortunately, the working definition for the diagnosis of idiopathic acute TM proposed by the Transverse Myelitis Consortium Working Group does not distinguish between APTM and complete TM or LETM. 8 Important differences in prognosis in patients with APTM compared with patients with LETM were recently described. 3 Patients with APTM remain at fairly high risk for the development of MS (range, 20%-30%), even when presenting with an initially normal cerebral MRI, in sharp contrast to patients with LETM. 9, 10 As the relatively low disability scores of our patients with APTM suggest, this syndrome seems to be clinically mild even when relapses occur. This stands in contrast to most patients with demyelinating disease associated with NMO-IgG positivity, wherein patients tend to have more severe relapses and disability long term. Longitudinal experience with patients with relapsing APTM was previously reported; these patients were not considered to have clinically definite MS given the limitation of pathological features (both clinically and radiographically) to the spinal cord only. 
